aloesin profile

aloesin: UP780 is a preparation of aloesin and an aloe polysaccharide that improves insulin sensitivity; human intestinal bacteria cleaves the C-glucosyl bond; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Aloe	genus	A plant genus of the family Xanthorrhoeaceae which is used medicinally. It contains anthraquinone glycosides such as aloin-emodin or aloe-emodin (EMODIN).[MeSH]	Asphodelaceae	[no description available]

Flora

Rank

Flora Definition

Family

Family Definition

Aloe

genus

A plant genus of the family Xanthorrhoeaceae which is used medicinally. It contains anthraquinone glycosides such as aloin-emodin or aloe-emodin (EMODIN).[MeSH]

Asphodelaceae

[no description available]

Cross-References

ID Source	ID
PubMed CID	160190
CHEMBL ID	5172191
CHEBI ID	2608
SCHEMBL ID	6936841
MeSH ID	M0190535

Synonyms (33)

Synonym
nsc631262
nsc-631262
4h-1-benzopyran-4-one, 8-.beta.-d-glucopyranosyl-7-hydroxy-5-methyl-2-(2-oxopropyl)-
aloe resin b
2-acetonyl-7-hydroxy-5-methyl-8-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one
C15539
30861-27-9
aloesin
C08994
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
y27m69y8es ,
4h-1-benzopyran-4-one, 8-beta-d-glucopyranosyl-7-hydroxy-5-methyl-2-(2-oxopropyl)-
nsc 631262
unii-y27m69y8es
S9284
aloesin [mi]
aloesin [inci]
CHEBI:2608
SCHEMBL6936841
AC-34460
8-beta-d-glucopyranosyl-7-hydroxy-5-methyl-2-(2-oxopropyl)-4h-1-benzopyran-4-one
DTXSID80184877
2-acetonyl-8-beta-d-glucopyranosyl-7-hydroxy-5-methylchromone
J-018171
AKOS030632376
HY-N2460
aloeresin
Q27105732
CCG-268585
CS-0022690
MS-26618
CHEMBL5172191 ,
bdbm50600326

Research Excerpts

Overview

Excerpt	Reference
"Aloesin is an active constituent of the herb aloe vera and plays a crucial role in anti-inflammatory activity, ultraviolet protection, and antibacterium. "	( Chen, XJ; Lu, HS; Lv, RW; Qu, XD; Wang, Y; Zhang, LQ, 2017)
"Aloesin is a chromone that is a component of Aloe spp. "	( Lynch, B; Roberts, A; Simon, R, 2011)
"Aloesin is a C-glycosylated chromone compound isolated from aloe, and it is difficult to synthesize because of C-glycosyl moiety in the molecule."	( Lee, SK; Park, HR; Park, JH; Park, MK; Park, YK; Piao, LZ, 2002)

Treatment

Excerpt	Reference
"Aloesin treatment accelerated wound closure rates in hairless mice by inducing angiogenesis, collagen deposition and granulation tissue formation."	( Chae, JK; Do, SG; Jeong, M; Kim, SY; Wahedi, HM; Yoon, H, 2017)
"Aloesin treatment suppressed pigmentation by 34%, arbutin by 43.5%, and the cotreatment by 63.3% compared with the control (n = 15; P < 0.05)."	( Choi, S; Chung, MH; Kim, JE; Lee, SK; Park, YI, 2002)

Drug Classes (1)

Class	Description
chromones	A chromenone that consists of a 1,4-benzopyrone skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	38.9000	0.0002	2.4585	9.9600	AID1891410
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (10)

Process	via Protein(s)	Taxonomy
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Process	via Protein(s)	Taxonomy
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay ID	Title	Year	Journal	Article
AID1891409	Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 peptide as substrate at 100 uM incubated for 30 mins by FRET based assay relative to control
AID1891410	Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 peptide as substrate incubated for 30 mins by FRET based assay
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	8 (20.00)	18.2507
2000's	14 (35.00)	29.6817
2010's	14 (35.00)	24.3611
2020's	4 (10.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe

Studies, This Drug (%)

All Drugs %

pre-1990

0 (0.00)

18.7374

1990's

8 (20.00)

18.2507

2000's

14 (35.00)

29.6817

2010's

14 (35.00)

24.3611

2020's

4 (10.00)

2.80

[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.44%)	5.53%
Reviews	2 (4.88%)	6.00%
Case Studies	1 (2.44%)	4.05%
Observational	0 (0.00%)	0.25%
Other	37 (90.24%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type

This drug (%)

All Drugs (%)

Trials

1 (2.44%)

5.53%

Reviews

2 (4.88%)

6.00%

Case Studies

1 (2.44%)

4.05%

Observational

0 (0.00%)

0.25%

Other

37 (90.24%)

84.16%

[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
nelfinavir mesylate	[no description available]	medium	1	0	methanesulfonate salt	antineoplastic agent; HIV protease inhibitor
calpeptin	[no description available]	medium	1	0	amino acid amide
calpain inhibitor 2	[no description available]	medium	1	0	peptide
celastrol	[no description available]	medium	1	0	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
tanshinone ii a	[no description available]	medium	1	0	abietane diterpenoid
anacardic acid	[no description available]	medium	1	0	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
acetylleucyl-leucyl-norleucinal	[no description available]	medium	1	0	aldehyde; tripeptide	cysteine protease inhibitor
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	[no description available]	medium	1	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
4,5,6,7-tetrachloroindan-1,3-dione	[no description available]	medium	1	0
telaprevir	[no description available]	medium	1	0	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
pd 151746	[no description available]	medium	1	0
l 685458	[no description available]	medium	1	0	carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic
mdl 201053	[no description available]	medium	1	0
mocetinostat	[no description available]	medium	2	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	[no description available]	medium	1	0	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
alloin	[no description available]	medium	7	0	diastereoisomeric mixture	EC 1.14.18.1 (tyrosinase) inhibitor; laxative
glucose, (beta-d)-isomer	[no description available]	medium	39	1	D-glucopyranose	epitope; mouse metabolite
emodin	[no description available]	medium	6	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
aloenin	[no description available]	medium	1	0	glycoside
zinc oxide	[no description available]	medium	1	0	zinc molecular entity
niacinamide	[no description available]	medium	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
arbutin	[no description available]	medium	5	1	beta-D-glucoside; monosaccharide derivative	Escherichia coli metabolite; plant metabolite
hydroquinone	[no description available]	medium	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
gw 1929	[no description available]	medium	1	0	benzophenones
tyrosine	[no description available]	medium	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
glycosides	[no description available]	medium	1	0
aloeresin a	[no description available]	medium	4	0	cinnamate ester
gold	[no description available]	medium	1	0	copper group element atom; elemental gold
leukotriene b4	[no description available]	medium	1	0	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
1-anilino-8-naphthalenesulfonate	[no description available]	medium	1	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
1,1-diphenyl-2-picrylhydrazyl	[no description available]	medium	1	0
thromboxane a2	[no description available]	medium	1	0	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
mannans	[no description available]	medium	1	0
tanshinone vi	[no description available]	medium	1	0
phenanthrenes	[no description available]	medium	1	0
benzo(a)pyrene	[no description available]	medium	1	0	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite
3-hydroxybenzo(a)pyrene	[no description available]	medium	1	0	ortho- and peri-fused polycyclic arene
acetone	[no description available]	medium	1	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
chromone-2-carboxylic acid	[no description available]	low	0	0	chromones
cromolyn	[no description available]	low	0	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	[no description available]	low	0	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
ono 1078	[no description available]	low	0	0	chromones
4-chromone	[no description available]	low	0	0	chromones; enone
3-methylchromone	[no description available]	low	0	0	chromones
4-chromanone	[no description available]	low	0	0	chromones
Chromone-3-carboxylic acid	[no description available]	low	0	0	chromones
biflorin	[no description available]	low	0	0	chromones
2-(2-phenylethyl)chromone	[no description available]	low	0	0	benzenes; chromones	plant metabolite
stigmatellin	[no description available]	low	0	0	aromatic ether; chromones; olefinic compound; phenols	bacterial metabolite; quinol oxidation site inhibitor
2-ethyl-3-[(4-methoxyphenyl)methyl][1]benzopyrano[2,3-d]pyrimidine-4,5-dione	[no description available]	low	0	0	chromones
N-(3-methyl-4-oxo-1-benzopyran-2-yl)carbamic acid ethyl ester	[no description available]	low	0	0	chromones
5-bromo-3-pyridinecarboxylic acid [3-(2-naphthalenyloxy)-4-oxo-1-benzopyran-7-yl] ester	[no description available]	low	0	0	chromones
3-pyridinecarboxylic acid [2-(2-furanyl)-4-oxo-1-benzopyran-3-yl] ester	[no description available]	low	0	0	chromones
2-thiophenecarboxylic acid [3-(3,5-dimethylphenoxy)-4-oxo-1-benzopyran-7-yl] ester	[no description available]	low	0	0	chromones
5-bromo-3-pyridinecarboxylic acid [3-(3-methylphenoxy)-4-oxo-1-benzopyran-7-yl] ester	[no description available]	low	0	0	chromones
4-[[7-methoxy-4-oxo-2-(trifluoromethyl)-1-benzopyran-3-yl]oxy]benzoic acid	[no description available]	low	0	0	chromones
N-(2,5-dimethylphenyl)-2-[[3-(4-ethylphenoxy)-4-oxo-1-benzopyran-7-yl]oxy]acetamide	[no description available]	low	0	0	chromones
2-amino-6-ethyl-3-(3-isoxazolyl)-7-methoxy-1-benzopyran-4-one	[no description available]	low	0	0	chromones
3-phenyl-2-propan-2-yl[1]benzopyrano[2,3-d]pyrimidine-4,5-dione	[no description available]	low	0	0	chromones
5-[(6-hydroxy-4-oxo-1-benzopyran-3-yl)methylidene]-1,3-diazinane-2,4,6-trione	[no description available]	low	0	0	chromones
acetic acid [6-ethyl-2-methyl-3-(1-methyl-2-benzimidazolyl)-4-oxo-1-benzopyran-7-yl] ester	[no description available]	low	0	0	chromones
4-[2-[(1'-acetyl-4-oxo-6-spiro[3,4-dihydro-2H-1-benzopyran-2,4'-piperidine]yl)oxy]-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester	[no description available]	low	0	0	chromones
1-(5-methyl-2-furanyl)-2-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-1H-[1]benzopyrano[2,3-c]pyrrole-3,9-dione	[no description available]	low	0	0	chromones
3-(4-methyl-1,3-dioxan-2-yl)-1-benzopyran-4-one	[no description available]	low	0	0	chromones
5,7-dihydroxychromone	[no description available]	low	0	0	chromones
noreugenin	[no description available]	low	0	0	chromones; resorcinols	plant metabolite
3-(1-benzimidazolyl)-6-ethyl-7-hydroxy-1-benzopyran-4-one	[no description available]	low	0	0	chromones
7-hydroxy-2-methyl-6-propyl-3-(2-pyridinyl)-1-benzopyran-4-one	[no description available]	low	0	0	chromones
3-[(2S,4S)-2-(4-hydroxybutoxy)-6-[4-morpholinyl(oxo)methyl]-3,4-dihydro-2H-pyran-4-yl]-1-benzopyran-4-one	[no description available]	low	0	0	chromones
(2R,4R)-2-[[4-(hydroxymethyl)phenyl]methoxy]-4-(4-oxo-1-benzopyran-3-yl)-3,4-dihydro-2H-pyran-6-carboxylic acid prop-2-enyl ester	[no description available]	low	0	0	chromones
1'-acetyl-6-[2-(4-ethyl-1-piperazinyl)-2-oxoethoxy]-4-spiro[3,4-dihydro-2H-1-benzopyran-2,4'-piperidine]one	[no description available]	low	0	0	chromones
5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one	[no description available]	low	0	0	alkaloid; chromones; hydroxypiperidine; resorcinols; tertiary amino compound	anti-inflammatory agent; anti-ulcer drug; anticholesteremic drug; antileishmanial agent; antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; fungal metabolite; plant metabolite
LSM-26549	[no description available]	low	0	0	chromones
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one	[no description available]	low	0	0	chromones

Condition	Relationship Strength	Studies	Trials
Abnormalities, Autosome	low	1	0
Abnormalities, Chromosomal	low	1	0
Abnormalities, Chromosome	low	1	0
Autosome Abnormalities	low	1	0
Body Weight	low	2	0
Cancer of Ovary	low	1	0
Cancer of the Ovary	low	1	0
Carcinogenesis	low	1	0
Carcinoma, Hepatocellular	low	1	0
Cardiac Remodeling, Ventricular	low	1	0
Chromosomal Aberrations	low	1	0
Chromosome Aberrations	low	1	0
Chromosome Abnormalities	low	1	0
Colitis	low	1	0
Colorectal Cancer	low	2	0
Colorectal Carcinoma	low	2	0
Colorectal Neoplasms	low	2	0
Colorectal Tumors	low	2	0
Cytogenetic Aberrations	low	1	0
Cytogenetic Abnormalities	low	1	0
Dermatoses	low	1	0
Dermatosis	low	1	0
Diabetes Mellitus, Adult-Onset	low	1	0
Diabetes Mellitus, Ketosis-Resistant	low	1	0
Diabetes Mellitus, Maturity-Onset	low	1	0
Diabetes Mellitus, Non Insulin Dependent	low	1	0
Diabetes Mellitus, Non-Insulin-Dependent	low	1	0
Diabetes Mellitus, Noninsulin Dependent	low	1	0
Diabetes Mellitus, Noninsulin-Dependent	low	1	0
Diabetes Mellitus, Slow-Onset	low	1	0
Diabetes Mellitus, Stable	low	1	0
Diabetes Mellitus, Type 2	low	1	0
Diabetes Mellitus, Type II	low	1	0
Disease Models, Animal	low	1	0
Emesis	low	1	0
Heart Disease, Ischemic	low	1	0
Hepatocellular Carcinoma	low	1	0
Hepatoma	low	1	0
Hypermelanosis	medium	2	1
Hyperpigmentation	medium	2	1
Incontinentia Pigmenti Achromians	low	1	0
Injuries, Radiation	medium	1	1
Injury, Myocardial Reperfusion	low	1	0
Insulin Resistance	low	1	0
Insulin Sensitivity	low	1	0
Invasiveness, Neoplasm	low	1	0
Ischemia, Myocardial	low	1	0
Ischemic Heart Disease	low	1	0
Ito Syndrome	low	1	0
Left Ventricle Remodeling	low	1	0
Left Ventricular Remodeling	low	1	0
Liver Cancer, Adult	low	1	0
Liver Cell Carcinoma	low	1	0
Liver Cell Carcinoma, Adult	low	1	0
Malignant Melanoma	low	1	0
Maturity-Onset Diabetes	low	1	0
Maturity-Onset Diabetes Mellitus	low	1	0
Melanoma	low	1	0
Metastase	low	1	0
Metastases, Neoplasm	low	1	0
Metastasis	low	1	0
Metastasis, Neoplasm	low	1	0
MODY	low	1	0
Myocardial Ischemia	low	1	0
Myocardial Ischemic Reperfusion Injury	low	1	0
Myocardial Remodeling, Ventricular	low	1	0
Myocardial Reperfusion Injury	low	1	0
Neoplasm Invasion	low	1	0
Neoplasm Invasiveness	low	1	0
Neoplasm Metastases	low	1	0
Neoplasm Metastasis	low	1	0
Neoplasms, Colorectal	low	2	0
Neoplasms, Ovarian	low	1	0
NIDDM	low	1	0
Noninsulin-Dependent Diabetes Mellitus	low	1	0
Oncogenesis	low	1	0
Ovarian Cancer	low	1	0
Ovarian Neoplasms	low	1	0
Ovary Cancer	low	1	0
Ovary Neoplasms	low	1	0
Pigmentation Disorders	low	1	0
Radiation Injuries	medium	1	1
Radiation Sickness	medium	1	1
Radiation Syndrome	medium	1	1
Reperfusion Injury, Myocardial	low	1	0
Schamberg Disease	low	1	0
Schamberg's Disease	low	1	0
Sensitivity and Specificity	low	2	0
Skin Aging	low	1	0
Skin and Subcutaneous Tissue Disorders	low	1	0
Skin Diseases	low	1	0
Tumorigenesis	low	1	0
Type 2 Diabetes	low	1	0
Type 2 Diabetes Mellitus	low	1	0
Ventricle Remodeling	low	1	0
Ventricular Remodeling	low	1	0
Vomiting	low	1	0
Weight Gain	low	2	0

Research Highlights

Safety/Toxicity (2)

Article	Year
In vivo safety evaluation of UP780, a standardized composition of aloe chromone aloesin formulated with an Aloe vera inner leaf fillet. Regulatory toxicology and pharmacology : RTP, Volume: 69, Issue: 3	2014
Subchronic toxicity evaluation of aloesin. Regulatory toxicology and pharmacology : RTP, Volume: 61, Issue: 2	2011
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (1)

Article	Year
Effects of aloe, aloesin, or propolis on the pharmacokinetics of benzo[a]pyrene and 3-OH-benzo[a]pyrene in rats. Journal of toxicology and environmental health. Part A, Dec-10, Volume: 68, Issue: 23-24	2005
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (1)

Article	Year
Subchronic toxicity evaluation of aloesin. Regulatory toxicology and pharmacology : RTP, Volume: 61, Issue: 2	2011
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

aloesin

Description